# 此超級綜合評分是基於以下評分的加權平均結果。

*biotech · news · 2026-05-27 · MarketScreener*

## Key points

- Trader 超級評分使用四個月的每股盈餘修正期進行計算。
- Investor 超級綜合評分包含一年的每股盈餘修正期，與 Trader 指標不同。
- 全球綜合評分要求至少涵蓋五項指定指標中的四項才能計算。
- 品質綜合評分只需涵蓋三個組成評分中的兩項即可產生。

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/us-fda-approves-abbvie-s-rare-blood-cancer-drug-ce7f5ad3dd8efe20)

---

Canonical: https://newsio.io/zh-TW/n/efd61530-1eee-4481-b14f-cfa02e852c83/
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works